Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Syndax Pharmaceuticals (SNDX) over the last 11 years, with Q3 2025 value amounting to $595000.0.

  • Syndax Pharmaceuticals' Other Accumulated Expenses rose 18605.77% to $595000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $595000.0, marking a year-over-year increase of 18605.77%. This contributed to the annual value of $421000.0 for FY2024, which is 5259.01% down from last year.
  • Per Syndax Pharmaceuticals' latest filing, its Other Accumulated Expenses stood at $595000.0 for Q3 2025, which was up 18605.77% from $618000.0 recorded in Q2 2025.
  • Over the past 5 years, Syndax Pharmaceuticals' Other Accumulated Expenses peaked at $3.2 million during Q3 2022, and registered a low of $188000.0 during Q3 2021.
  • In the last 5 years, Syndax Pharmaceuticals' Other Accumulated Expenses had a median value of $604000.0 in 2022 and averaged $938631.6.
  • As far as peak fluctuations go, Syndax Pharmaceuticals' Other Accumulated Expenses soared by 159468.09% in 2022, and later crashed by 8313.33% in 2023.
  • Syndax Pharmaceuticals' Other Accumulated Expenses (Quarter) stood at $1.7 million in 2021, then tumbled by 64.49% to $604000.0 in 2022, then surged by 47.02% to $888000.0 in 2023, then plummeted by 52.59% to $421000.0 in 2024, then surged by 41.33% to $595000.0 in 2025.
  • Its Other Accumulated Expenses was $595000.0 in Q3 2025, compared to $618000.0 in Q2 2025 and $576000.0 in Q1 2025.